Marinomed Biotech AG

Marinomed Biotech AG is an Austria-based biopharmaceutical company founded in 2006 as a spin-off from the University of Veterinary Medicine Vienna. It specializes in developing innovative medicinal products and medical devices targeting viral infectious diseases and autoreactive immune disorders in virology and immunology. The company leverages two proprietary, patent-protected technology platforms: Marinosolv®, which enhances the solubility and efficacy of poorly soluble active ingredients for therapies in allergies, autoimmune diseases, and sensitive tissues like eyes, nose, and lungs; and Carragelose®, a virus-blocking compound from red seaweed used in six nasal sprays, throat sprays, and lozenges sold globally in over 40 countries through partners. Marinomed maintains a lean business model focused on research, preclinical and clinical development, and outlicensing to pharmaceutical partners for commercialization. With around 50 employees, headquartered in Korneuburg, it lists on the Vienna Stock Exchange and offers over-the-counter products like allergen-blocking nasal sprays and moisturizing eye drops, advancing a pipeline of late-stage projects.